Mr Vashu Pamnani
Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.
The products and services Cambridge Bioscience offers includes:
· Ion Channel, GPCR & Kinase Profiling Services
· Primary screening & Secondary Drug Profiling Services
· Cardiac Safety Assessment
· Ion Channel & GPCR Cell Lines
· Human Tissues, TMAs & Biofluids
· Primary Cells & Cell Culture Technologies
To find out more, please meet us at the event or contact us using the details below
Cambridge Bioscience
Munro House
Trafalgar Way
Bar Hill
Cambridge
United Kingdom
CB23 8SQ
Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Email: support@bioscience.co.uk
Website: www.bioscience.co.uk
Cambridge Bioscience
Business Manager
Mr Christopher Parsons
UKTI London's private sector International Trade Advisers support London based companies to develop their business internationally. This is achieved via provision of advice, training and delivery of UKTI services.
Supported by the Mayor's Export Program UKTI London is bringing a trade mission to Bio-Europe. Kit Malthouse the Deputy Mayor of London for Business and Enterprise will be meeting the mission delegates at a networking breakfast on Tuesday Nov 5th.
UK Trade & Investment - London Region
International Trade Adviser
Ms Mairaedh Pedersen
Quay Pharma is one of the world’s leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing.
Quay provides formulation, analytical development and clinical trials manufacturing for companies world-wide. Applying strong project management, products are quickly and cost effectively taken from pre-clinical through phase II trials. Having deep knowledge in solid dosage form development, particularly improving bioavailability of NCEs, has resulted in many clients successfully licensing products on to large pharmaceutical companies.
Quay Pharma
Chief Executive Officer
Dr Keith Powell
Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.
Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.
Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing. In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.
Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.
To find out more, please meet us at the event or contact us using the details below
Canbex Therapeutics Ltd
London BioScience Innovation Centre
2 Royal College Street
London
NW1 0NH
Tel: +44 (0)207 554 5872
Email: enquiries@canbex.co.uk
